Cargando…

Cross-cultural adaptation of the CHO-KLAT for boys with hemophilia in rural and urban china

BACKGROUND: Quality of life (QoL) is increasingly recognized as an important outcome measure in clinical trials. The Canadian Hemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) shows promise for use in China. OBJECTIVE: To adapt the CHO-KLAT version 2.0 for use in clinical trials in China. MET...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Runhui, Zhang, Jishui, Luke, Koon Hung, Wu, Xinyi, Burke, Tricia, Tang, Ling, Poon, Man-Chiu, Li, Xiaojing, Zhou, Min, Sun, Jing, Hang, Marrisa, Blanchette, Victor, Young, Nancy L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499387/ https://www.ncbi.nlm.nih.gov/pubmed/22978454 http://dx.doi.org/10.1186/1477-7525-10-112

Ejemplares similares

Updating the Canadian Hemophilia Outcomes–Kids’ Life Assessment Tool (CHO‐KLAT) in the era of extended half‐life clotting factor concentrates
por: Price, Victoria E., et al.
Publicado: (2021)

Cross-cultural adaptation and validation of the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) in Côte d’Ivoire (the Ivory Coast)
por: Lambert, Catherine, et al.
Publicado: (2020)

Significant reduction in hemarthrosis in boys with severe hemophilia A: The China hemophilia individualized low‐dose secondary prophylaxis study
por: Wu, Runhui, et al.
Publicado: (2021)

Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study
por: Chen, Zhen-Ping, et al.
Publicado: (2018)

Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half‐life factor VIII concentrates
por: Huang, Kun, et al.
Publicado: (2022)

Impact of prophylaxis on health‐related quality of life of boys with hemophilia: An analysis of pooled data from 9 countries
por: Usuba, Koyo, et al.
Publicado: (2019)

Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
por: Li, Zekun, et al.
Publicado: (2019)

Social participation and hemophilia: Self‐perception, social support, and their influence on boys in Canada
por: Chiu, Aubrey S., et al.
Publicado: (2021)

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
por: Li, Zekun, et al.
Publicado: (2021)

The impact of extended half‐life factor concentrates on patient reported health outcome measures in persons with hemophilia A and hemophilia B
por: Sun, Haowei (Linda), et al.
Publicado: (2021)

Magnetic resonance imaging in boys with severe hemophilia A: Serial and end‐of‐study findings from the Canadian Hemophilia Primary Prophylaxis Study
por: Stimec, Jennifer, et al.
Publicado: (2021)

PK‐tailored tertiary prophylaxis in patients with severe hemophilia A at Beijing Children's Hospital
por: Li, Peijing, et al.
Publicado: (2019)

Individualized prophylaxis for optimizing hemophilia care: can we apply this to both developed and developing nations?
por: Poon, Man-Chiu, et al.
Publicado: (2016)

Exploration of the minimum necessary FVIII level at different physical activity levels in pediatric patients with hemophilia A
por: Ai, Di, et al.
Publicado: (2022)

Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A
por: Chen, Zhenping, et al.
Publicado: (2021)

A previously treated severe haemophilia A patient developed high-titre inhibitor after vaccinations
por: Li, Zekun, et al.
Publicado: (2020)

Development and desensitization therapy of high-response factor VIII inhibitors with severe allergic reaction in a moderate hemophilia A patient
por: Liu, Guoqing, et al.
Publicado: (2021)

Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions
por: Jackson, Shannon C, et al.
Publicado: (2015)

T2 mapping magnetic resonance imaging of cartilage in hemophilia
por: Brakel, Benjamin A., et al.
Publicado: (2023)

T2 mapping in the quantitative evaluation of articular cartilage changes in children with hemophilia: A pilot study
por: Zhang, Ningning, et al.
Publicado: (2019)

F9 mutations causing deletions beyond the serine protease domain confer higher risk for inhibitor development in hemophilia B
por: Liu, Guoqing, et al.
Publicado: (2023)

Real-world experience of emicizumab prophylaxis in young children with hemophilia A: retrospective data from China
por: Liu, Guoqing, et al.
Publicado: (2022)

Measuring the impact of hemophilia on families: Development of the Hemophilia Family Impact Tool (H‐FIT)
por: Dover, Saunya, et al.
Publicado: (2021)

Autism spectrum disorders in boys at a major UK hemophilia center: prevalence and risk factors
por: Bladen, Melanie, et al.
Publicado: (2022)

Risk factors for inhibitors in hemophilia A based on RNA‐seq and DNA methylation
por: Liu, Wei, et al.
Publicado: (2022)

CASE REPORT Spontaneous Forearm Compartment Syndrome in a Boy With Hemophilia A: A Therapeutic Dilemma
por: Kim, Jennifer, et al.
Publicado: (2013)

Ketogenic low‐CHO, high‐fat diet: the future of elite endurance sport?
por: Burke, Louise M.
Publicado: (2020)

Hemophilia prophylaxis adherence and bleeding using a tailored, frequency‐escalated approach: The Canadian Hemophilia Primary Prophylaxis Study
por: Dover, Saunya, et al.
Publicado: (2020)

Severe Hemophilia A and Moyamoya Syndrome in a 19-Year-Old Boy Caused by Xq28 Microdeletion
por: Tzeravini, Evangelia, et al.
Publicado: (2022)

Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
por: Wu, Runhui, et al.
Publicado: (2020)

Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
por: Xu, Qian, et al.
Publicado: (2023)

Influence of cell culture media and feed supplements on cell metabolism and quality of IgG produced in CHO-K1, CHO-S, and CHO-DG44
por: Reinhart, David, et al.
Publicado: (2015)

High efficiency CHO cell display-based antibody maturation
por: Luo, Ruiqi, et al.
Publicado: (2020)

Adenomatoid Tumor of the Tunica Albuginea in a Boy: A Case Report and Literature Review
por: Guo, Kaimin, et al.
Publicado: (2015)

Clinical outcomes in hemophilia: Towards development of a core set of standardized outcome measures for research
por: Dover, Saunya, et al.
Publicado: (2020)

Retrovectors packaged in CHO cells to generate GLP-1-Fc stable expression CHO cell lines
por: Li, Jing, et al.
Publicado: (2019)

Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A
por: Zhao, Yongqiang, et al.
Publicado: (2021)

Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
por: Sun, Jie, et al.
Publicado: (2022)

The value of usability testing for Internet-based adolescent self-management interventions: “Managing Hemophilia Online”
por: Breakey, Vicky R, et al.
Publicado: (2013)

F8 gene mutation spectrum in severe hemophilia A with inhibitors: A large cohort data analysis from a single center in China
por: Sun, Jie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_73ctm9lvjvilhqin1vucnorl8c